{"filing":{"accession_number":"0001438533-26-000054","cik":"0001438533","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"tvtx-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/tvtx-20260706.htm"},"events":[{"id":16902,"run_id":15126,"accession_number":"0001438533-26-000054","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Sandra Calvin, the Company's chief accounting officer and principal accounting officer, provided notice on July 6, 2026 of her intention to retire following the filing of the 2027 Form 10-K. While the disclosure also mentions John Torell's expected appointment as her successor, the principal disclosed action is Ms. Calvin's departure. The retirement of a principal accounting officer is material to investors as it affects financial reporting oversight and internal controls.","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15142,"accession_number":"0001438533-26-000054","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Sandra Calvin, the Company's chief accounting officer and principal accounting officer, provided notice on July 6, 2026 of her intention to retire following the filing of the 2027 Form 10-K. While the disclosure also mentions John Torell's expected appointment as her successor, the principal disclosed action is Ms. Calvin's departure. The retirement of a principal accounting officer is material to investors as it affects financial reporting oversight and internal controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:51:41.735154+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15142,"accession_number":"0001438533-26-000054","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Sandra Calvin, the Company's chief accounting officer and principal accounting officer, provided notice on July 6, 2026 of her intention to retire following the filing of the 2027 Form 10-K. While the disclosure also mentions John Torell's expected appointment as her successor, the principal disclosed action is Ms. Calvin's departure. The retirement of a principal accounting officer is material to investors as it affects financial reporting oversight and internal controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:51:41.735154+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-07-09"}]}